81 results about "Tetracyclic triterpenoids" patented technology

The invention provides a sweet crystal of grosvenor momordica with the type of free sugar and health care and a method thereof, which includes that tetracyclic triterpene water extract is extracted from grosvenor momordicas. The character is that modified starch with certain proportion is added into the tetracyclic triterpene water extract of grosvenor momordica, spray-drying and oven-drying are carried out, then the product is finished after being crushed through 60 mesh sieve. The sweet crystal has the color of light brown, keeps the medicinal function of grosvenor momordica and dissolves in water completely. The solution has good taste and special flavor. After drinking the solution, people do not feel sour in mouth, and the taste of sweet cool can be kept in mouth for a few minutes. The sweet crystal is convenient for use. The added quantity is almost the same as the quantity of the traditional habit.

The invention relates to an ocular preparation for preventing and treating cataract and a preparation method of the ocular preparation. The ocular preparation comprises in weight percentage, 0.1%-10% of lanostane tetracyclic triterpenoid compounds and 90%-99.9% of auxiliary materials. The ocular preparation is stable in quality and simple and convenient in preparation process, and pharmacodynamic evaluation is performed.

The invention relates to a group of glycosyl transferases and applications of the glycosyl transferases. Particularly, the invention provides applications of glycosyl transferases gGT25, gGT13, gGT30, gGT25-1, gGT25-3, gGT25-5, gGT29, gGT29-3, gGT29-4, gGT29-5, gGT29-6, gGT29-7, 3GT1, 3GT2, 3GT3 and 3GT4, and derived peptides of the glycosyl transferases in glycosylation catalysis and new saponin synthesis of terpenoids. The glycosyl transferases can specifically and efficiently catalyze hydroxyl glycosylation of C-20 bit and / or C-6 bit and / or C-3 of a tetracyclic triterpenoid compound substrate, and / or transfers the glycosyl groups from glycosyl donors to the first glycosyl groups of the C-3 bit and C-6 bit of the tetracyclic triterpenoid compound to extend a carbohydrate chain. The glycosyl transferases disclosed by the invention can also be applied to building synthetic rare ginsenosides and a plurality of novel ginsenosides and derivatives of the ginsenosides.

The invention provides the application of tetracyclic triterpenoids compound cucurbitacins E in preparing anti-angiogenic drugs. The cucurbitacins E can inhibit tumor angiogenesis, arthritis pathological tissue vessel angiogenesis, neovascular eye disease, hemangioma pathological tissue angiogenesis, psoriasis pathological tissue vessel angiogenesis, solid tumor pathological tissue angiogenesis, hemangioma, Kaposi' s sarcoma pathological tissue angiogenesis, leukocythemia, lymphadenoma, myeloma blood cancer and Paget' s disease angiogenesis. The invention also provides the application of a compound containing effective dose of cucurbitacins E and pharmacy acceptable ingredients in preparing the anti-angiogenic drugs.

The invention relates to a method for detecting dammarane tetracyclic triterpenoid saponin and secondary aglycone. The inventive method uses high-efficiency liquid color spectrum-mass spectrum coupled device, wherein the conditions of high-efficiency liquid color spectrum comprises: color spectrum column is ODSC18 column; the column temperature is 20-38Deg. C; the conditions of mass spectrum comprise: the ion source is Turbo Ionspray source; the ejecting voltage is 3000-5000V; the Tem is 250-300Deg. C; the detector uses triplicate four-electrode serial mass spectrum detection and positive ion detection; the scanning method uses multi-reaction detection (MRM); CE is 17-36V; DP is 8-110V; the ion detection comprises: processing impact induce dissociation on the quasi-molecule ion peak of said saponin of first-stage scanning mass spectrum, to obtain the second-stage fragment ion; and uses multi-reaction detection (MRM) scanning method to analyze the ion reaction quantitatively, to represent the blood drug density of monomer saponin and secondary aglycone.

The invention relates to a pharmaceutical composition with dammarane-type tetracyclic triterpene compound as an active component and an application thereof to the pharmaceutical field. Panax notoginseng is separated to obtain three dammarane-type tetracyclic triterpene compounds as shown in the following structural formula, in vitro pharmacological experiments show that the pharmaceutical composition has good in vitro inhibitory activity for herpes simplex virus type I and can be applied to the preparation of medicines for resisting herpes simplex virus type I and is used for treating herpetic keratitis, encephalitis, pneumonia, ulcerative stomatitis, blister and the like caused by herpes simplex virus type I.

The invention relates to saponin compounds or pharmaceutically acceptable salts thereof, compositions, and a preparation method of the saponin compounds or the pharmaceutically acceptable salts thereof, and application of the saponin compounds or the pharmaceutically acceptable salts therof and the compositions. Chemical components of gynostemma pentaphylla are subjected to systematic extraction,separation and purification by using various column chromatographic separation methods, and the compound having a dammarane tetracyclic triterpenoid structures and containing a glycosyl group in a side chain is obtained through separation. The compounds obtained by separation according to a technical scheme in the invention have anti-inflammatory, anti-tumor, antioxidant and lipid-lowering activities and the like.

Provided is an oil or fat composition including the following components (A) and (B): (A) a tetracyclic triterpene alcohol selected from the group consisting of 24-methylene cycloartanol and cyclobranol; and (B) an oil or fat containing diacylglycerol at 5 weight % or more.

The invention relates to a Hemsleya cucurbitane tetracyclic triterpenoid compound with a structural formula (I) which is described in the specification. In the structural formula (I), R1 is H and R2 is H; or, R1 is beta-D-Glc, and R2 is Ac. The invention further relates to a pharmaceutical composition with the compound as an active component and application of the compound and the pharmaceutical composition in drugs used for treating lung adenocarcinoma and colorectal carcinoma.

The invention discloses a new compound pseuoginsenoside-Rh2, a preparation method of the compound and an application of the compound to preparation of a tumor treating medicine. Both the compound and the ginsenoside-Rh2 are tetracyclic triterpenoid compounds; beta-D-glucopyranose is boned at the positions 3 of the compound and the ginsenoside-Rh2 respectively; the structures of the lateral chains are different; and both the compound and the ginsenoside-Rh2 have degradation products of panoxadiol saponin and have an anticancer effect.

The invention relates to novel hemsleya amabilis cucurbitane tetracyclotriterpene compounds disclosed as structural formula (I) or structural formula. The invention also relates to a pharmaceutical composition using the compounds as active ingredients and application of the compounds and pharmaceutical composition in drugs for treating lung adenocarcinoma, colon cancer and prostate cancer.

The invention discloses a method for extracting refined astragaloside from astragaliradix. Astragaloside is a lanolin alcohol-form tetracyclic triterpenoid saponin compound. A Chinese herbal medicine astragaliradix is rich in astragaloside. The method utilizes a series of high-efficiency extraction, separation and purification technical processes of ethanol reflux extraction, alkaline hydrolysis, macroporous resin purification, ion-exchange resin decoloration and recrystallization to realize extraction of a target compound which is white powder and has a yield more than 0.07% and purity more than 99%. The method is simple, can be operated easily, does not produce pollution and is suitable for large-scale production.

The invention provides a preparation method of a cucurbitacin type compound. The preparation method comprises the steps of extracting pedicellus melo by using an organic solvent, performing solvent distribution on an extract, and performing silica gel column separation and purification by high performance liquid chromatography on a sample after concentration to obtain a cucurbitacin mixture and a cucurbitaceae type compound. Through an anti-aging yeast model-K6001 yeast cell, an active ingredient, namely the cucurbitacin type compound is proved to be capable of significantly prolonging the replicative life span of yeast, so that the cucurbitacin mixture and the cucurbitaceae type compound can be applied in preparation of medicaments for preventing and treating aging and preventing or / and treating age-related diseases. Simultaneously, the cucurbitacin mixture and the cucurbitaceae type compound can also be applied in preparation of nutritional compositions for delaying aging and preventing age-related diseases. The compound can also be used as a lead compound for optimizing the structure and can be applied in preparation of medicaments for delaying aging and preventing or / and treating age-related diseases. The general formula of the structure of the compound is shown in the specification.

The invention relates to a novel hemsleya amabilis cucurbitane tetracyclic triterpene compound shown as the structural formula (I) in the specification. The invention further relates to a pharmaceutical composition using the compound as an active ingredient, as well as the application of the compound and the pharmaceutical composition in drugs for the treatment of adenocarcinoma of lung and colon cancer.

The invention relates to glycosyltransferases, mutants and application thereof. Specifically, the invention provides an in vitro glycosylation method provided comprisescomprising the following steps:transferring glycosyl groups of a glycosyl donor to C-3 hydroxy groups of tetracyclic triterpenoids in the presence of glycosyltransferase to form glycosylated tetracyclic triterpenoids, wherein the glycosyltransferase is glycosyltransferase or derivated polypeptide derivatives thereof shown as SEQ ID NO.4, or glycosyltransferase or derivated polypeptide derivatives thereof shown as SEQ ID NO.21.

The invention relates to novel glycosyltransferase derived from bacillus subtilis and application thereof. Specifically, the invention provides novel glycosyltransferase BsUGT1 derived from bacillus subtilis, a polynucleotide coding the glycosyltransferase, a vector containing the polynucleotide, and recombinant cells containing the vector or integrated with the polynucleotide. The BsUGT1 is capable of catalyzing hydroxyglycosylation on sites C3, C12 and / or C20 of a dammarane type tetracyclic triterpenoid compound. The invention further provides a method for performing glycosylation by using the glycosyltransferase, and a method for producing rare ginsenosides by using the glycosyltransferase. The glycosyltransferase is capable of catalyzing to produce multiple rare ginsenosides and novelrare ginsenosides (3beta, 12beta-Di-O-G1c-PPT), particularly a rare ginsenoside subjected to C12 glycosylation.

The invention belongs to the technical field of medicine, and particularly relates to an application of tetracyclic-triterpene-like compound-like cucurbitacine B separated and extracted from cucurbitaceous plants as a cancerous inhibitor of protein phosphatase 2A. Cucurbitacine B is taken as a main component in the cancerous inhibitor of protein phosphatase 2A, so that the expression of the cancerous inhibitor of protein phosphatase 2A can be inhibited remarkably. The cucurbitacine B can be applied to independent administration or combined treatment, including combined applications with radiotherapy, chemotherapy, surgical treatment, other growth factor inhibitors and sexual hormone inhibitors, any tumor treatment medicament and method.

The invention discloses tetracyclic triterpenoids shown as in structural formula (I), i.e., shionone triterpenes including astatarone C (1), astatarone G (2) and astatarone H (3), preparation methods of the shionone triterpenes and applications of the shionone triterpenes to the preparation of drugs for preventing and treating hepatitis B viruses (HBV) and the preparation of liver protection foods and health care products, wherein R in the formula represents anti-HBV drugs taking the shionone triterpenes as active components. Test results prove that the triterpenoids provided by the invention have a better anti-HBV activity and can be used for preparing the anti-HBV drugs. A new source is provided for finding the anti-HBV drugs. An extracting and separating method provided by the invention is good in controllability and repeatability, lower in cost and more convenient to operate.

The ecological farm chemical is one kind of extractive, which is extracted from wild conifer and other several plant materials and contains tetracyclotriterpene, aminooligose, aromatic oil, isoprene and plant activators. It makes plant produce systemic acquired resistance, induces the inner immunological mechanism of plant and thus prevents and treats diseases. It has low use amount, easy degradation, no obvious residue, low cost, wide, application range and other features, and it has especially obvious inhibition to blast and cyanosis of cotton.

The invention discloses a 3,4-dammarane tetracyclic triterpenoid compound with the structural formula shown in formulas (1)-(4). The invention further discloses an extraction method and application ofthe 3,4-dammarane tetracyclic triterpenoid compound. The 3,4-dammarane tetracyclic triterpenoid compoundcan significantly increase the consumption of insulin resistance adipocyte glucose, inhibit generation of IR adipocyte FFA, reduce the content of free fatty acid in cells and activate PPAR<gamma> to a certain extent.

The invention relates to a pharmaceutical composition with dammarane-type tetracyclic triterpene compound ginsenoside Rh4 as shown in the following structural formula and 20(S)-protopanaxatriol as the active components and the application thereof to the pharmaceutical field. The in vitro pharmacological experiments show that the pharmaceutical composition has good in vitro inhibitory activity for coxsackie B3 virus and can be used for treating viral myocarditis caused by coxsackie B3 virus.

The inventor researches Panax pseudoginseng Wall. var. notoginseng (Burkill) Hoo et Tseng antitumor activity, separates a tetracyclic triterpenoid monomer compound (with a code name of Y1218) from an active part of saponin and identifies a molecular structure of the tetracyclic triterpenoid monomer compound through modern spectroscopy. The tetracyclic triterpenoid monomer compound has antitumor effects.

The invention provides an application of anwuweizic acid in preparation of a medicine for preventing and treating hepatitis virus, wherein anwuweizic acid is a tetracyclic triterpenoid compound. The invention also provides an application of anwuweizic acid in preparation of food and health care products for protecting liver. According to the invention, the application of the tetracyclic triterpenoid compound namely anwuweizic acid in preparing the medicine for resisting hepatitis B virus (HBV) and hepatitis C virus (HCV) is provided; and the test result proves that the tetracyclic triterpenoid compound has remarkable activity in the aspect of resisting HBV and HCV, and is especially capable of inhibiting HCV to invade target cells, thus being used for preparing the medicine for resisting HBV and HCV. The invention provides a new source for finding out the medicine for resisting HBV and HCV.

The invention provides mastic tetracyclic triterpenoid components with 11 beta-hydroxysteroid dehydrogenase 1 inhibitory activity, a composition of the mastic tetracyclic triterpenoid components and application, and novel application of mastic tetracyclic triterpenoid components with structures of the general formulas I-IV as 11 beta-HDS inhibitors. As a class of 11 beta-HSD inhibitors in novel structure types, the mastic tetracyclic triterpenoid components have certain selective inhibition effects on 11 beta-HSD1 and are expected to be developed into medicine for regulating lipid metabolism and treating diabetes, obesity, cardiovascular diseases and the like.

The invention discloses low-sugar health type grosvenor momordica instant coffee. The low-sugar health type grosvenor momordica instant coffee is prepared from the following raw materials in parts by weight: 30-50 parts of fragrant and sweet grosvenor momordica essence, 20-30 parts of ground coffee and 20-30 parts of skim milk powder. The low-sugar health type grosvenor momordica instant coffee is prepared by the steps of weighing the raw materials in parts by weight, uniformly mixing, adding ethyl alcohol with the moisture quantity of 75-90 percent to prepare a soft material, sieving the soft material by a screen with 32-40 meshes to obtain particles, drying at 80 DEG C, carrying out particle classification by a screen with 12-14 meshes, selecting particles by a screen with 32-40 meshes, weighing, and quantitatively packaging to obtain the low-sugar health type grosvenor momordica instant coffee. According to the invention, the fragrant and sweet grosvenor momordica essence is used for replacing sugar, a sweet component of the grosvenor momordica essence is not sugar but tetracyclic triterpenoids and the grosvenor momordica essence does not have heat; as the characteristics of the fragrant and sweet grosvenor momordica essence and the ground coffee are organically combined to prepare the instant coffee, the instant coffee is convenient to drink, and when a person enjoys the instant coffee, grosvenor momordica has the health function of nourishing the oral cavity, the throat and the lung of a human body and the effect of purifying the internal environment of the human body.

The invention discloses tetracyclic triterpenoid compounds and a preparation method thereof. Bitter gourd leaves are adopted as a raw material, then subjected to 90% ethanol reflux extraction to be concentrated into an extract and then subjected to extraction with ethyl acetate, silica gel column chromatography separation, high performance liquid chromatography preparation and magnetic resonance imaging structural identification to successfully extract and separate the 4 kinds of tetracyclic triterpenoid compounds with the purity of more than 95%. According to the preparation method, the high-purity tetracyclic triterpenoid compounds can be separated and purified. The method is simple, feasible, good in reproducibility, fast and efficient, high in product purity and suitable for separationand preparation of various types of natural compounds from the bitter gourd leaves, thereby laying a technical foundation for screening active compounds from the bitter gourd leaves.

The invention relates to a group of high-activity glycosyl transferases responsible for sugar chain extension and an application of the glycosyl transferases. Specifically, the invention provides glycosyl transferase and a derivative polypeptide thereof, which can efficiently catalyze the reaction of extending sugar chains on the first glycosyl at the C-20 site and the first glycosyl at the C-6 site of a tetracyclic triterpenoid substrate. The ginsenoside products such asginsenoside Rb1, the ginsenoside Rb3, the ginsenoside DMGG, the ginsenoside DMGX, the gynostemma pentaphyllum saponin LXXV, the gynostemma pentaphyllum saponin XVII, the gynostemma pentaphyllum saponin XIII, gynostemma pentaphyllum saponin IX, notoginsenoside U and the notoginsenoside R1, notoginsenoside R2, notoginsenoside R3, 3-O-beta-(D-xylopyranosyl)-beta-(D-glucopyranosyl)-CK, 20-O-glucosyl ginsenoside Rf, Rd-C20-O-Rha, ginsenoside Rg2, and ginsenoside Re and the like can be obtained. The glycosyl transferase disclosed by the invention can also be applied to construction of artificially synthesized ginsenoside and a plurality of new ginsenosides and derivatives thereof.